Won Jin Ho

Won Jin Ho

Auto-generated profile, based on publicly available information

Won Jin Ho

Johns Hopkins University 2 Baltimore, MD

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KLKaysia Ludford
Kaysia Ludford
WHWon Jin Ho
Won Jin Ho
JTJane V. Thomas
Jane V. Thomas
KRKanwal P.S. Raghav
Kanwal P.S. Raghav
MMMariela A Blum Murphy
Mariela A Blum Murphy
MOMichael J. Overman
Michael J. Overman
PURPOSE: Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS: This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3 weeks for 6 months followed by surgical resection with an option to continue therapy for 1 year followed by observation. To continue on study, patients are required to have radiographic or clinical benefit. The coprimary end points are safety and pathologic complete response. Key secondary end points are response rate and organ-sparing at one year for patients who declined surgery. Exploratory analyses include interrogation of the tumor immune microenvironment using imaging mass cytometry. RESULTS: A total of 35 patients were enrolled, including 27 patients with colorectal cancer and eight patients with noncolorectal cancer. Among 33 evaluable patients, best overall response rate was 82%. Among 17 (49%) patients who underwent surgery, the pathologic complete response rate was 65%. Ten patients elected to receive one year of pembrolizumab followed by surveillance without surgical resection (median follow-up of 23 weeks [range, 0-54 weeks]). An additional eight did not undergo surgical resection and received less than 1 year of pembrolizumab. During the study course of the trial and subsequent follow-up, progression events were seen in six patients (four of whom underwent salvage surgery). There were no new safety signals. Spatial immune profiling with imaging mass cytometry noted a significantly closer proximity between granulocytic cells and cytotoxic T cells in patients with progressive events compared with those without progression. CONCLUSION: Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies.

25 October 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DSDaniel H. Shu
Daniel H. Shu
WHWon Jin Ho
Won Jin Ho
LKLuciane Kagohara
Luciane Kagohara
AGAlexander Girgis
Alexander Girgis
SSSarah M. Shin
Sarah M. Shin
MYMark Yarchoan
Mark Yarchoan

31 August 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
WHWon Jin Ho
Won Jin Ho
MYMark Yarchoan
Mark Yarchoan
AHAlex Hopkins
Alex Hopkins
RMRanee Mehra
Ranee Mehra
SGStuart Grossman
Stuart Grossman
HKHyunseok Kang
Hyunseok Kang
Background Low absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC may also be associated with response to immunotherapy. This study explores whether response to PD1 inhibitors in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is associated with pretreatment ALC. Methods Thirty-four R/M HNSCC patients who received either nivolumab or pembrolizumab between January 2014 and May 2018 at Johns Hopkins were identified retrospectively. Pretreatment blood counts in patients with and without clinical benefit from PD1 inhibitors were compared. Time-to-progression analyses were performed by dichotomizing the study cohort with the threshold of ALC 600 cells/μl, which is approximately 1.5 standard deviations away from treatment-naïve baseline mean. Results Patients with lower ALC appeared to have significantly less clinical benefit from anti-PD1 therapy. Those patients with pretreatment ALC < 600 cells/μl also had shorter PFS than patients with pretreatment ALC ≥ 600 cells/μl (median PFS 60 days vs. 141 days, p < 0.05). These results were consistent with multivariate proportional hazards analyses demonstrating significant association with progression. These observations were further supported by an expansion cohort analysis incorporating additional fourteen R/M HNSCC patients who received other checkpoint immunotherapy regimens at our institution. Conclusions This study for the first time demonstrates that pretreatment ALC is significantly associated with response to PD1 inhibitors in R/M HNSCC patients.

29 July 2021 in Cancer Cell
Verified
Journal Article
Closed access
EDEmily F. Davis-Marcisak
Emily F. Davis-Marcisak
ADAtul Deshpande
Atul Deshpande
GSGenevieve L. Stein-O’BRien
Genevieve L. Stein-O’BRien
WHWon J. Ho
Won J. Ho
DLDaniel Laheru
Daniel Laheru
LKLuciane Kagohara
Luciane Kagohara

17 September 2010 in Cancer Science
Verified
Journal Article
Closed access
PDF file
WHWon Jin Ho
Won Jin Ho
EPEdward A. Pham
Edward A. Pham
JKJun W. Kim
Jun W. Kim
CNChristopher W. Ng
Christopher W. Ng
JKJae H. Kim
Jae H. Kim
BWBenjamin M. Wu
Benjamin M. Wu

16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
JAJose M. Adrover
Jose M. Adrover
XHXiao Han
Xiao Han
LSLijuan Sun
Lijuan Sun
TFTakeo Fujii
Takeo Fujii
NSNicole Sivetz
Nicole Sivetz
MEMikala Egeblad
Mikala Egeblad
Tumour necrosis is associated with poor prognosis in cancer1,2 and is thought to occur passively when tumour growth outpaces nutrient supply. Here we report, however, that neutrophils actively induce tumour necrosis. In multiple cancer mouse models, we found a tumour-elicited Ly6GHighLy6CLow neutrophil population that was unable to extravasate in response to inflammatory challenges but formed neutrophil extracellular traps (NETs) more efficiently than classical Ly6GHighLy6CHigh neutrophils. The presence of these ‘vascular-restricted’ neutrophils correlated with the appearance of a ‘pleomorphic’ necrotic architecture in mice. In tumours with pleomorphic necrosis, we found intravascular aggregates of neutrophils and NETs that caused occlusion of the tumour vasculature, driving hypoxia and necrosis of downstream vascular beds. Furthermore, we found that cancer cells adjacent to these necrotic regions (that is, in ‘perinecrotic’ areas) underwent epithelial-to-mesenchymal transition, explaining the paradoxical metastasis-enhancing effect of tumour necrosis. Blocking NET formation genetically or pharmacologically reduced the extent of tumour necrosis and lung metastasis. Thus, by showing that NETs drive vascular occlusion, pleomorphic necrosis and metastasis, we demonstrate that tumour necrosis is not necessarily a passive byproduct of tumour growth and that it can be blocked to reduce metastatic spread.